Progress

From GATC to CPNDS

CPNDS began in 2005 as Genotype-specific Approaches to Therapy in Childhood (GATC). GATC functioned until 2009 when it evolved and was renamed CPNDS to reflect its larger role and its new funding partners.

The GATC consortium established an active ADR surveillance network that is unique in the world. It began with one surveillance site at BC Children’s Hospital, an agency of the Provincial Health Services Authority, and grew to include 13 major paediatric teaching hospitals across Canada. GATC developed its first pharmacogenomic panel of single nucleotide polymorphisms (SNPs) to study the genetics of ADRs in 2005. This panel allowed for the detection of genetic variation in over 220 key candidate genes that influence the way patients respond to a given medication. Over time, additional SNP panels have been developed for specific drug pathways and the initial panel has been further refined to include the most relevant and important SNP markers for solving drug safety problems.

In January 2009 when GATC evolved to become CPNDS, there were over 18,000 ADR cases and matched controls enrolled in the project.

Because of our efforts, we were able to discover the genetic basis of infant mortality from maternal use of codeine analgesia and the genetic basis of cisplatin-induced deafness in children.

We’re growing!

In 2009, we expanded our pharmacogenomics research capacity by building a new, dedicated facility capable of housing both our clinic and lab-based teams. This facility also allows us to do high-throughput genome sequencing. It is located on more than 750 square metres of lab space in the BC Mental Health & Addictions Research Institute co-located with the Child & Family Research Institute, on the campus of BC Children’s Hospital and BC Women’s Hospital & Health Centre, agencies of the Provincial Health Services Authority, in Vancouver, British Columbia.

Plans to Expand the Research:

  • New ADR surveillance in adult patients with cancer throughout the province of British Columbia
  • Developing new ADR targets in response to critical drug safety needs identified by clinicians and regulators
  • New pediatric sites around the world